AlphAIAlphAI — Financial news for AI agents
pro.thestreet.comAUG 213 min read$MRNA

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

Original reporting
pro.thestreet.com
Published Aug 21, 2026, 3:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 9:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
After Moderna’s Big News, Here Are Three Biotechs to Watch — source image
Source · pro.thestreet.com
Decision brief

The 30-second read

$MRNABullishHigh
01

Why it matters

These events collectively boost sector sentiment, offering short‑term trading opportunities across the highlighted stocks.

02

Market read

Biotech sector sees a multi‑stock rally; traders can target the highlighted names for momentum plays.

03

What to watch

Potential competition in skin‑cancer space and reliance on single‑product pipelines could limit upside.

Relevance 9/10Novelty 9/10Timing: Wednesday intraday

Background

The article reviews recent biotech catalysts, highlighting a rally driven by trial data and legal settlements.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

Moderna disclosed positive Phase 3 skin cancer trial data, driving a 175% intraday price surge.

Expected impact

Expect continued upside on regulatory progress; target $250 if approval path remains clear.

Evidence & confidence

Large-cap biotech with breakthrough data and massive price move indicates strong market reaction.

$MRKBullishMedium confidence
Context

Merck reported positive Phase 3 skin cancer trial results, lifting the stock over 12%.

Expected impact

Potential incremental rally to $150 as investors price in future sales.

Evidence & confidence

Mid-cap biotech with solid trial outcome; move is notable but less dramatic than Moderna.

$AUPHBullishMedium confidence
Context

Aurinia settled a litigation with Teva, securing exclusivity on Lupkynis until 2036 and received an upgrade.

Expected impact

Short-term upside to $22 as analysts raise targets.

Evidence & confidence

Legal win and analyst upgrade provide clear catalyst for share appreciation.

$OCULBullishLow confidence
Context

Ocular Therapeutix received reiterated buy ratings after competitor missed endpoint and its own Phase 3 wet AMD data.

Expected impact

Potential modest rally to $30 on continued analyst support.

Evidence & confidence

Analyst sentiment shift without new data; impact likely limited.

$PGENBullishMedium confidence
Context

Precigen highlighted strong Q2 sales of Papzimeos ($53M) and outlook for cash‑flow breakeven by year‑end.

Expected impact

Possible move toward $8‑$9 as investors price in profitability timeline.

Evidence & confidence

Solid earnings beat for a small-cap biotech; market may reward near‑term performance.

Market effects

Sector

Biotech sector gains momentum as multiple companies report positive trial data and legal wins.

Regional

U.S. biotech indices likely to outpace broader market today.

Global

Positive biotech news may lift global health‑care ETFs and attract foreign capital.

Counterpoint

What could challenge this read

Rapid price spikes may be overbought; caution on potential regulatory setbacks.

Key entities

  • company
    Moderna

    Biotech firm with positive Phase 3 skin cancer data.

  • company
    Merck

    Pharma giant with supportive trial results.

  • company
    Aurinia Pharmaceuticals

    Secured exclusivity on Lupkynis via settlement.

  • company
    Ocular Therapeutix

    Received buy rating reiterations after competitor miss.

  • company
    Precigen

    Reported strong sales of Papzimeos and breakeven outlook.

Read at source← All news

Related articles

OCT 15
$MRNAMed

Moderna Stock Jumps 4.5% as Major Cancer Vaccine Catalyst Approaches

Moderna (MRNA) shares rose 4.5% as investors await detailed results from a Phase 3 cancer trial with Merck (MRK). The trial, involving 1,137 patients, showed the treatment reduced cancer recurrence. Results will be presented on October 24. Moderna reported a Q2 net loss of $782 million. Barclays estimates potential $3 billion annual melanoma sales by 2035, split equally with Merck.

tipranks.com6 min
OCT 15
$MRNAMed

Moderna (MRNA) Shares Surge on Cancer Vaccine Data Ahead of Late

Moderna (MRNA) shares rose 38% since late September ahead of a presentation on late-stage trial data for its cancer vaccine, developed with Merck (MRK). The rally follows a 170% surge after positive Phase 3 melanoma trial results in August. Moderna's P/S ratio is 41.76, significantly higher than its historical median of 8.48, reflecting market growth expectations despite its unprofitability. Insider activity shows no purchases and $64.6M in sales over the past year.

gurufocus.com6 min
OCT 15
$MRKMed

Pennsylvania secures $4 billion in investments, governor says

Pennsylvania Governor Josh Shapiro announced $4 billion in life sciences and private-sector investments. Merck committed $2.9 billion for expansion, including $550 million for a robotics and AI facility. GSK pledged over $800 million for a biopharmaceutical hub. State and federal funds will support port expansions, totaling $837.5 million. These investments are expected to create 6,300 jobs.

finance.yahoo.com2 min
OCT 15
$MRKHighAI 9/10

Merck & Co., Inc. (MRK) Reports Promising Skin Cancer Trial Results for Keytruda and Personalized mRNA Vaccine

Merck & Co. (MRK) reported promising results from a phase 3 skin cancer trial, showing improved survival rates with its personalized mRNA vaccine and Keytruda. The stock has a one-month return of 2.40% and a 52-week range of $82.01 to $156.92, closing at $147.37 on October 14, 2026, with a market cap of $372.30 billion. Baillie Gifford highlighted MRK in its Q3 2026 investor letter, noting the trial results.

finance.yahoo.com2 min